Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
The PIK3CA gene is mutated with high frequency in human breast cancers.
|
15254419 |
2004 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our study indicates that blocking PI3K pathway activation mediated by HER-2/neu overexpression may be useful in the treatment of breast tumors with HER-2/neu overexpression and wild-type p53.
|
15625017 |
2004 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
|
15647370 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.
|
15805248 |
2005 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.
|
15805248 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.
|
15805248 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We identified a 20.6% (19 of 92) and 33.3% (5 of 15) PIK3CA somatic mutation frequency in primary breast tumors and cell lines, respectively.
|
16168105 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We identified a 20.6% (19 of 92) and 33.3% (5 of 15) PIK3CA somatic mutation frequency in primary breast tumors and cell lines, respectively.
|
16168105 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome.
|
16317585 |
2006 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome.
|
16317585 |
2006 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
|
16582596 |
2006 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
|
17006756 |
2007 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
|
17936563 |
2007 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We also found that male breast cancers display PIK3CA mutations at an overall frequency similar to that observed in female breast tumors.
|
18022911 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
|
18074223 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In comparing deregulation of oncogenic pathways between age groups, a higher probability of PI3K (p = 0.006) and Myc (p = 0.03) pathway deregulation was observed in breast tumors arising in younger women.
|
18167534 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
|
18183466 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we found that VEGF-A 165 (recombinant protein or breast tumor cell-secreted) is also capable of inducing migration of VEGFR2-negative human aortic smooth muscle cells (hAOSMCs), and this induction is mediated through a molecular cross-talk of neuropilin-1 (NRP-1), VEGFR1 (Flt-1), and phosphoinositide 3-kinase (PI3K)/Akt signaling kinase.
|
18284215 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors.
|
18371219 |
2008 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
|
18679714 |
2008 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
|
18990689 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
|
19027487 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
|
19196980 |
2009 |